MedPath
HSA Approval

ZOLEDRONIC ACID FRESENIUS KABI CONCENTRATE FOR SOLUTION FOR INFUSION 4MG/5ML

SIN14934P

ZOLEDRONIC ACID FRESENIUS KABI CONCENTRATE FOR SOLUTION FOR INFUSION 4MG/5ML

ZOLEDRONIC ACID FRESENIUS KABI CONCENTRATE FOR SOLUTION FOR INFUSION 4MG/5ML

February 1, 2016

FRESENIUS KABI (SINGAPORE) PTE LTD

FRESENIUS KABI (SINGAPORE) PTE LTD

Regulatory Information

FRESENIUS KABI (SINGAPORE) PTE LTD

FRESENIUS KABI (SINGAPORE) PTE LTD

Therapeutic

Prescription Only

Formulation Information

INFUSION, SOLUTION CONCENTRATE

INTRAVENOUS

Medical Information

M05BA08

zoledronic acid

Manufacturer Information

FRESENIUS KABI (SINGAPORE) PTE LTD

Fresenius Kabi Austria GmbH (Plant Graz)

Active Ingredients

Zoledronic acid monohydrate 4.264mg/5ml eqv Zoledronic acid anhydrous

4mg/5ml

Zoledronic acid

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ZOLEDRONIC ACID FRESENIUS KABI CONCENTRATE FOR SOLUTION FOR INFUSION 4MG/5ML - HSA Approval | MedPath